Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 8/20 | 0.52 |
| ▸ | NPY1R | P25929 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 5/20 | 0.47 |
| ▸ | MASP2 | O00187 | 2/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | NPY4R | P50391 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16181237 | 1.00 | FURIN (0.52) | FURINNPY1RF2MASP2ITGB3 | |
| SCHEMBL7920067 | 1.00 | FURIN (0.52) | FURINNPY1RF2MASP2ITGB3 | |
| SCHEMBL16181249 | 0.96 | FURIN (0.49) | FURINNPY1RF2MASP2ITGB3 | |
| SCHEMBL16181263 | 0.96 | FURIN (0.49) | FURINNPY1RF2MASP2ITGB3 | |
| SCHEMBL16181278 | 0.96 | FURIN (0.54) | FURINNPY1RITGB3ITGA2BNPY2R | |
| SCHEMBL16181274 | 0.94 | NPY1R (0.51) | FURINNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL16181255 | 0.94 | NPY1R (0.51) | FURINNPY1RF2MASP2ITGB3 | |
| SCHEMBL16181267 | 0.93 | FURIN (0.52) | FURINNPY1RITGB3ITGA2BNPY2R | |
| SCHEMBL16181256 | 0.93 | NPY1R (0.58) | FURINNPY1RF2MASP2ITGB3 | |
| SCHEMBL16181266 | 0.93 | NPY1R (0.49) | FURINNPY1RF2MASP2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865865-B2 | N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic | PHILIPPS-UNIVERSITAT MARBURG (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20110312873-A1 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | PHILIPPS-UNIVERSITAT MARBURG (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312873-A1 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | FURIN, IAPP, APP | FURIN 1/4885NPY1R 540/4885F2 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.